Adenine Base Editor Therapeutics 2026 — PatSnap Eureka
Adenine Base Editor Therapeutics: 2026 Patent & Innovation Landscape
Adenine base editors (ABEs) are at a critical inflection point — progressing from foundational Harvard patents to clinical-stage single-AAV delivery and disease-specific applications covering up to 47.8% of pathogenic SNPs. Explore the full IP and research landscape with PatSnap Eureka.
How Adenine Base Editors Work — and Why They Matter
Adenine base editors (ABEs) function by tethering an evolved E. coli tRNA adenosine deaminase A (TadA) to a Cas9 nickase domain, directing the fusion protein to a target genomic locus via a guide RNA (sgRNA). The TadA component deaminates adenosine to inosine within the editing window on the non-complementary DNA strand; inosine is read as guanosine during replication, effectively installing an A•T-to-G•C transition without introducing double-strand breaks.
Because approximately 47.8% of known pathogenic single-nucleotide polymorphisms (SNPs) in humans can theoretically be corrected by this conversion, the clinical relevance is substantial. The ClinVar database catalogues tens of thousands of such variants across monogenic diseases, hemoglobinopathies, and cardiovascular conditions — all potential targets for ABE-based therapies.
The foundational molecular architecture — Cas9 nickase fused to TadA with optional nuclear localization sequences (NLS) and inosine-repair inhibitors — is described across multiple active patents assigned to President and Fellows of Harvard College in jurisdictions including Singapore, Israel, and Japan. The life sciences IP landscape has since expanded rapidly, with directed evolution producing generation-step variants from ABE7.10 through ABE8e and the precision-tuned ABE9.
Delivery remains the critical engineering challenge: full-length ABE8e exceeds the approximately 5 kb packaging capacity of adeno-associated virus (AAV) vectors, driving a parallel innovation cluster around compact Cas9 orthologs and size-minimized ABE constructs. According to FDA gene therapy guidance, delivery optimization is a primary regulatory consideration for IND-enabling studies.
ABE Efficiency, Precision & Delivery Data
Key performance metrics across ABE generations and delivery modalities, derived from patent and literature analysis via PatSnap Eureka.
Relative Editing Efficiency by ABE Generation
ABE8 achieved 3.2× higher efficiency than ABE7.10; ABE8e showed 4.2-fold improvement at non-NGG PAM sites; ABE9 prioritises precision over raw efficiency.
Single-AAV ABE8e In Vivo Tissue Editing Efficiency
Size-minimized single-AAV ABE8e achieved 66% liver, 33% heart, and 22% muscle editing via retro-orbital injection in mice (HHMI/Harvard, 2022).
Four Core Technology Clusters Shaping the ABE Landscape
Patent and literature analysis via PatSnap Eureka identifies four distinct innovation clusters driving adenine base editor development from 2018 to 2025.
Cas9-TadA Fusion Architecture — Core ABE Platform
The canonical ABE design consists of an evolved TadA monomer or heterodimer fused to a Cas9 nickase (nCas9, D10A variant), with one or two NLS sequences. The Harvard portfolio documents progression from early ecTadA variants (D108N, D108G, A106V/D108N) through multi-mutation constructs including L84F, H123Y, I156F, A142N, H36L, R51L, S146C, K157N, and K161T. Active patents span Singapore (2018, 2019, 2021), Israel (2018, 2019), and Japan (2023, 2025).
Harvard College · Active across IL, SG, JPTadA Directed Evolution — ABE8 and ABE8e Generation
The TadA-8e variant carries eight amino acid mutations relative to TadA-7.10 that increase DNA-binding affinity via electrostatic mechanisms — specifically higher positive charge density in the binding region — and improve protein stability. ABE8e achieves substantially higher on-target editing, particularly at non-NGG PAM sites (~4.2-fold improvement versus ABE7.10) and in primary human cells. Beam Therapeutics (2020) and Fudan University (2023) are key contributors to this cluster.
Beam Therapeutics · Fudan University · UCSDReduced Off-Target Editing — uABE, e-ABE, and ABE9
A distinct cluster from 2019–2022 addresses ABE safety by engineering variants with reduced RNA off-target editing (R153 deletion to disrupt TadA-tRNA binding, yielding Upgraded ABE/uABE), reduced Cas9-independent DNA off-target activity (high-fidelity SpCas9 substitution, e-ABE), and narrowed editing windows. ABE9 (N108Q/L145T mutations) achieves a 1–2 nt editing window with up to 342.5-fold precision improvement over ABE8e at homopolymeric adenosine sites, with undetectable Cas9-independent DNA off-target effects.
East China Normal Univ. · Guangzhou Univ. · Sun Yat-senCompact Cas9 Variants & Single-AAV Engineering
Given that full-length ABE8e exceeds the ~5 kb AAV packaging limit, this cluster targets delivery engineering via compact orthologous Cas9 proteins (Nme2Cas9 with N4CC PAM), size-minimized ABE8e variants fitting within single-AAV genomes, and retro-orbital injection protocols. Three compact ABE8e variants fitting within single-AAV capacity were demonstrated by HHMI/Harvard (2022), each achieving liver (66%), heart (33%), and muscle (22%) editing. Dual-AAV trans-splicing intein systems represent an interim approach being superseded by single-AAV solutions.
HHMI / Harvard · UMass Medical · Sirius Univ.ABE Application Domains: From Hemoglobinopathies to Cardiovascular Disease
Adenine base editors have been validated across multiple therapeutic areas, with hemoglobinopathies and cardiovascular disease defining the first clinical wave.
| Therapeutic Area | Key Target / Mechanism | Efficacy Data | Lead Institutions | Stage |
|---|---|---|---|---|
| Hemoglobinopathies (SCD, β-Thal) | HBG1/HBG2 promoter editing — fetal hemoglobin (HbF) reactivation | Up to 60% efficiency in human CD34+ HSCs; NG-ABEmax-KR >4× improvement at gamma-globin promoters | Beam Therapeutics; Wenzhou Medical University | Clinical-adjacent |
| Cardiovascular (Hypercholesterolemia) | PCSK9 & ANGPTL3 knockdown via single-AAV ABE | 93% average knockdown of circulating PCSK9/Angptl3; substantial reductions in plasma cholesterol and triglycerides | Howard Hughes Medical Institute / Harvard University | Preclinical (mouse) |
| Monogenic Rare Diseases (Broad) | A→G correction of pathogenic point mutations; ~47.8% of SNPs addressable | Validated across diverse human and mouse disease-relevant loci | NIH; Sirius University of Science and Technology | Preclinical |
| Immunology / Cell Therapy | T cell engineering; CAR-T manufacturing; immune checkpoint disruption | 98–99% target modification in primary human T cells (ABE8s, mRNA delivery); multiplexed across 3 loci simultaneously | Beam Therapeutics | Clinical-adjacent |
| Agriculture / Crop Engineering | Trait improvement; herbicide resistance in rice, wheat, cotton, tobacco | TadA8e toolkit validated across diverse genomic contexts and polyploid species | Shandong Normal University; South China Agricultural University | Active research |
Map ABE therapeutic IP across all disease areas
Use PatSnap Eureka's IP analytics platform to identify competitive white space across monogenic disease indications.
Strategic Implications for R&D and IP Teams
Based on patent prosecution patterns, literature clusters, and assignee activity in this dataset, five strategic signals emerge for gene therapy R&D and IP teams.
Harvard IP Remains the Dominant Chokepoint
Multiple active patents across IL, SG, and JP jurisdictions — with a 2025 JP continuation still in prosecution — indicate Harvard's foundational ABE IP will constrain freedom-to-operate for commercial ABE programs through at least the mid-2030s. New entrants must either license through Beam Therapeutics or develop non-infringing TadA variants via alternative deaminase scaffolds or PAM-variant Cas9 combinations. Review IP due diligence frameworks before initiating development.
Delivery Engineering Is the Primary Near-Term Differentiator
The transition from dual-AAV to single-AAV compact ABE systems is now technically validated; organizations that secure IP around specific size-minimized ABE-Cas9 combinations, tissue-targeting capsid serotypes, and dose-reduction delivery strategies will command commercial advantage as IND filings accelerate. The EMA advanced therapy framework is actively tracking AAV delivery developments.
Four Emerging Directions Defining ABE's Next Phase
Publications from 2022–2025 in this dataset identify four primary directions that will shape the ABE competitive landscape through 2030.
Single-AAV Delivery — Tissue Reach vs. Dual-AAV
Three compact ABE8e variants fitting within single-AAV capacity were demonstrated by HHMI/Harvard (2022), each achieving multi-tissue editing at lower doses than dual-AAV systems.
Computational ABE Prediction — ABEdeepon Training Scale
ABEdeepon deep learning model trained on 60,615 targets enables prediction of on-target efficiency and outcome frequencies from sgRNA sequence alone, shifting ABE from empirical to rational design.
Harvard Dominates Core IP; Chinese Academics Lead Precision Engineering
Dominant assignee: President and Fellows of Harvard College. In this dataset, Harvard holds the largest concentration of active granted patents across multiple jurisdictions: Israel (IL, 2018 and 2019), Singapore (SG, 2018, 2019, and 2021), and Japan (JP, 2023 and 2025). All Harvard-assigned ABE patents retrieved carry active legal status, indicating a robust and maintained foundational IP position. The 2025 JP continuation filing signals IP runway extending well into the 2030s.
Key commercial assignee: Beam Therapeutics. Beam Therapeutics (Cambridge, MA, USA) appears in this dataset as the primary commercial entity publishing ABE8 development and therapeutic application data (2020), representing the principal licensee and commercialization partner for Harvard's foundational IP. Teams seeking licensing pathways should monitor Beam's patent prosecution activity closely.
Academic innovation distributed globally. Literature-generating institutions span the United States (HHMI/Harvard, UMass, UCSD, NIH), China (Fudan, East China Normal, South China Agricultural, Shandong Normal, Sun Yat-sen, Wenzhou Medical), and Russia (Sirius University). Chinese academic institutions account for a notably high proportion of precision engineering and efficiency optimization publications in the 2020–2023 period — a pattern consistent with broader WIPO innovation index trends in life sciences.
Jurisdiction concentration note. Among retrieved patents with active legal status, Singapore (SG), Israel (IL), and Japan (JP) are the represented prosecution jurisdictions. The absence of explicitly retrieved US or EP granted ABE patents in this dataset is a data limitation — not an indicator of absence in those jurisdictions. Comprehensive FTO analysis should extend to USPTO and EPO databases via PatSnap's analytics platform.
Adenine Base Editor Therapeutics — Key Questions Answered
Approximately 47.8% of known pathogenic single-nucleotide polymorphisms (SNPs) in humans can theoretically be corrected by the A•T-to-G•C conversion that adenine base editors perform, making the clinical relevance substantial.
ABE8 variants achieved approximately 3.2× higher editing efficiency than ABE7.10 at challenging loci, and up to 60% efficiency in human CD34+ cells for fetal hemoglobin reactivation, as demonstrated by Beam Therapeutics in 2020.
Full-length ABE8e exceeds the approximately 5 kb packaging capacity of adeno-associated virus (AAV) vectors. Strategies to address this include using compact orthologous Cas9 proteins such as Nme2Cas9, size-minimized ABE8e variants fitting within single-AAV genomes, and dual-AAV trans-splicing intein systems.
Size-minimized single-AAV ABE8e variants achieved 66% editing in mouse liver, 33% in heart, and 22% in muscle via retro-orbital injection, as demonstrated by Howard Hughes Medical Institute and Harvard University in 2022.
The President and Fellows of Harvard College hold the largest concentration of active granted ABE patents across multiple jurisdictions including Israel (IL), Singapore (SG), and Japan (JP), with a 2025 JP continuation filing indicating IP runway extending well into the 2030s. Beam Therapeutics is the primary commercial licensee.
ABE9, engineered with N108Q and L145T mutations in TadA-8e by East China Normal University (2022), achieves a 1–2 nt editing window with undetectable Cas9-independent DNA off-target effects and up to 342.5-fold precision improvement over ABE8e at homopolymeric adenosine sites.
Still have questions about the ABE patent landscape? Let PatSnap Eureka answer them for you.
Ask PatSnap EurekaMap the Full Adenine Base Editor IP Landscape Before Your Competitors Do
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from ABE delivery IP gaps to therapeutic white space and FTO analysis.
References
- Adenosine nucleobase editors and uses thereof — President and Fellows of Harvard College, 2019, IL
- Adenosine nucleobase editors and uses thereof — President and Fellows of Harvard College, 2019, SG
- Adenosine nucleobase editors and their uses — President and Fellows of Harvard College, 2023, JP
- Adenosine nucleobase editors and their uses — President and Fellows of Harvard College, 2025, JP
- Nucleobase editors and uses thereof — President and Fellows of Harvard College, 2018, SG
- Nucleobase editors and uses thereof — President and Fellows of Harvard College, 2018, IL
- Nucleobase editors and uses thereof — President and Fellows of Harvard College, 2021, SG
- Directed Evolution of Adenine Base Editors with Increased Activity and Therapeutic Application — Beam Therapeutics, 2020
- Adenine Base Editing in vivo with a Single Adeno-Associated Virus Vector — University of Massachusetts Medical School, 2021
- Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors — Howard Hughes Medical Institute / Harvard University, 2022
- Directed-evolution mutations of adenine base editor ABE8e improve its DNA-binding affinity and protein stability — Fudan University, 2023
- Engineering precise adenine base editor with infinitesimal rates of bystander mutations and off-target editing — East China Normal University, 2022
- Upgraded adenine base editor (uABE) with minimized RNA off-targeting activity — Guangzhou University, 2020
- Human cell based directed evolution of adenine base editors with improved efficiency — Wenzhou Medical University, 2021
- Improving the specificity of adenine base editor using high-fidelity Cas9 — Sun Yat-sen University, 2019
- Targeting fidelity of adenine and cytosine base editors in mouse embryos — US National Institutes of Health, 2018
- Translational potential of base-editing tools for gene therapy of monogenic diseases — Sirius University of Science and Technology, 2022
- Retracing the evolutionary trajectory of adenine base editors using theoretical approaches — University of California San Diego, 2020
- BEdeepon: an in silico tool for prediction of base editor efficiencies and outcomes — University of Illinois College of Medicine, 2021
- Accelerated drug resistant variant discovery with an enhanced, scalable mutagenic base editor platform — Genentech, 2023
- Generation of a high-efficiency adenine base editor with TadA8e for developing wheat dinitroaniline-resistant germplasm — Shandong Normal University, 2022
- PhieABEs: a PAM-less/free high-efficiency adenine base editor toolbox with wide target scope in plants — South China Agricultural University, 2022
- ClinVar — National Center for Biotechnology Information (NCBI), NIH
- Global Innovation Index — World Intellectual Property Organization (WIPO)
- Cellular & Gene Therapy Products — U.S. Food and Drug Administration (FDA)
- Advanced Therapy Medicinal Products — European Medicines Agency (EMA)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This landscape is derived from a targeted set of patent and literature records and represents a snapshot of innovation signals within this dataset only; it should not be interpreted as a comprehensive view of the full industry.
PatSnap Eureka searches patents and research to answer instantly.